Supplemental material
Open access
2,231
Views
18
CrossRef citations to date
0
Altmetric
Original Research
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review
Meta H. M. DiekstraDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands
, Jesse J. SwenDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands
, Hans GelderblomDepartment of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
& Henk-Jan GuchelaarDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NetherlandsCorrespondence[email protected]
Pages 605-618
|
Received 01 Dec 2015, Accepted 27 Jan 2016, Published online: 17 Feb 2016
Related Research Data
Useless Until Proven Effective: The Clinical Utility of Preemptive Pharmacogenetic Testing
Source:
Springer Nature
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Source:
Oxford University Press (OUP)
Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
Source:
American Association for Cancer Research (AACR)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Source:
American Society of Clinical Oncology (ASCO)
Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma
Source:
Springer Nature
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review
Source:
Figshare
ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma
Source:
Oxford University Press (OUP)
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
Source:
Springer Nature
Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
Source:
Springer Nature
EMMPRIN Promotes Angiogenesis, Proliferation, Invasion and Resistance to Sunitinib in Renal Cell Carcinoma, and Its Level Predicts Patient Outcome
Source:
Public Library of Science (PLoS)
Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics
Source:
Japanese Society for the Study of Xenobiotics
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Source:
Massachusetts Medical Society
Evidence Required to Demonstrate Clinical Utility of Pharmacogenetic Testing: The Debate Continues
Source:
Springer Nature
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
Source:
Springer Nature
Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
Source:
Springer Nature
Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib
Source:
Springer Nature
High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
Source:
Bentham Science Publishers Ltd.
DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
Source:
Public Library of Science (PLoS)
Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
Source:
American Society of Clinical Oncology (ASCO)
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Source:
Massachusetts Medical Society
MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib
Source:
Elsevier BV
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Source:
Massachusetts Medical Society
A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
Source:
American Association for Cancer Research (AACR)
Soluble Isoforms of Vascular Endothelial Growth Factor Are Predictors of Response to Sunitinib in Metastatic Renal Cell Carcinomas
Source:
Public Library of Science (PLoS)
Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma
Source:
Public Library of Science (PLoS)
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
Source:
American Association for Cancer Research (AACR)
L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells
Source:
Oxford University Press (OUP)
The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer
Source:
American Association for Cancer Research (AACR)
A Case of Adult Metastatic Xp11 Translocation Renal Cell Carcinoma Treated Successfully With Sunitinib
Source:
Elsevier BV
The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma
Source:
American Association for Cancer Research (AACR)
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
Source:
Oxford University Press (OUP)
The Effect of ABCG2 Genotype on the Population Pharmacokinetics of Sunitinib in Patients With Renal Cell Carcinoma
Source:
Ovid Technologies (Wolters Kluwer Health)
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
Source:
Springer Nature
A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma
Source:
Elsevier BV
Biochemical and molecular markers in renal cell carcinoma: an update and future prospects
Source:
Informa UK Limited
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
Source:
Springer Nature
Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib
Source:
Bentham Science Publishers Ltd.
Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
Source:
American Society of Clinical Oncology (ASCO)
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Source:
Elsevier BV
InterpretingPValues in Pharmacogenetic Studies: A Call for Process and Perspective
Source:
American Society of Clinical Oncology (ASCO)
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib
Source:
Informa UK Limited
Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients
Source:
Springer Nature
Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization
Source:
Elsevier BV
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Source:
American Association for Cancer Research (AACR)
Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Source:
American Association for Cancer Research (AACR)
CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma
Source:
Elsevier BV
Building the evidentiary framework for pharmacogenetic testing: is it time to move beyond randomized controlled trials?
Source:
Future Medicine Ltd
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
Source:
Oxford University Press (OUP)
Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma
Source:
Public Library of Science (PLoS)
Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662
Source:
Springer Nature
Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma
Source:
Ovid Technologies (Wolters Kluwer Health)
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis
Source:
Informa UK Limited
MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients
Source:
Elsevier BV
Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
Source:
American Society of Clinical Oncology (ASCO)
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
Source:
Oxford University Press (OUP)
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine
Source:
Springer Nature
Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma
Source:
Elsevier BV
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms†
Source:
Oxford University Press (OUP)
Quantification of Plasma Cell-Free DNA1in Predicting Therapeutic Efficacy of Sorafenib on Metastatic Clear Cell Renal Cell Carcinoma
Source:
Hindawi Limited
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Source:
Elsevier BV
A Multigene Assay Identifying Distinct Prognostic Subtypes of Clear Cell Renal Cell Carcinoma with Differential Response to Tyrosine Kinase Inhibition
Source:
Elsevier BV
Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors.
Source:
Future Medicine Ltd
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.